Friday, Oct 07, 2022

Glenmark gets final FDA nod for migraine headache relief drug

Glenmark said the drug is "therapeutical equivalent of Endo Pharmaceutical's Frova tablets 2.5 mg."

Glenmark Pharmaceuticals. Glenmark Pharmaceuticals.

Glenmark Pharma has received final nod from the USFDA to manufacture and market therapeutical equivalent of Endo Pharmaceutical’s Frova tablets, used to treat migraine headaches, in the American market.

“Glenmark Pharmaceuticals Inc has been granted final approval by the US Food and Drug Administration (US FDA) for Frovatriptan Succinate Tablets, 2.5 mg,” the company said in a BSE filing on Monday.

It further said the drug is “therapeutical equivalent of Endo Pharmaceutical’s Frova tablets 2.5 mg.”


Subscriber Only Stories
JK Cement’s SPSU Udaipur Launches ‘Golden Batch 2022’ In Collaboration Wi...Premium
Appendicitis in Children- A new lifestyle disorderPremium
Re-Defining The Tradition In Folk Art: An Art Educator’s PerspectivePremium
Symbiosis School of Sports Sciences (SSSS) launches undergraduate program...Premium

Quoting IMS data, Glenmark said the approved product has an estimated market size of $87.8 million for the 12 months ended January 2016.

The company’s current portfolio consists of 61 ANDAs pending approvals from the US FDA and 108 products authorised for distribution in the US.

Stock of Glenmark Pharma was trading at Rs 831.90, down 2.03 per cent from the previous close on BSE.

First published on: 14-03-2016 at 01:12:10 pm
Next Story

Kesha fans protest in New York

Latest Comment
Post Comment
Read Comments